Tilogotamab (Anti-TNFRSF10B / TRAILR2 / CD262) is an agonistic hexamer formation-enhanced mixture of two antibodies that target two separate epitopes on death receptor type 5 (DR5). It can be used for the research of multiple myeloma (MM). MW :144.88 KD.